Imagine First
TESAMORELIN
TESAMORELIN
Couldn't load pickup availability
A 44-amino-acid Growth Hormone–Releasing Hormone analog developed to engage endogenous growth hormone signaling at the pituitary level. In controlled clinical research settings, Tesamorelin has been studied for its association with measurable reductions in visceral adipose tissue, observed alongside changes in growth hormone activity.
For Research Use Only
Current Batch:
10MG : IF-8688689
TESAMORELIN - 10MG - COA
Understanding the Science
Studied Biological Pathways
Growth Hormone–Releasing Hormone Receptor Engagement
Metabolic Signaling Pathways Overview
Insulin-Like Growth Factor 1 Pathways Involved in Lipid Metabolism
Latest Clinical Trial Data
Phase 3 EGRIFTA Clinical Trials in Human Immunodeficiency Virus–Associated Lipodystrophy
18.2%
Average Visceral Fat Reduction at 26 Weeks
Visceral Adipose Tissue Change
Tesamorelin vs Placebo
- Tesamorelin — 26 weeks: −15.4%
- Tesamorelin — 52 weeks: −17.5%
- Placebo: −5.0%
Trial details:
Data derived from two Phase 3 clinical trials involving 816 human immunodeficiency virus–infected patients with lipodystrophy. The primary endpoint was percent change in trunk fat, specifically visceral adipose tissue, measured by computed tomography scan at 26 weeks.
Treatment Outcomes
Key Clinical Milestones
Percentage of participants achieving clinical endpoints
73% of participants
Achieved greater than 8% reduction in visceral adipose tissue
Primary responders
91.2% of participants
Well tolerated
Completed treatment
52 weeks
Effects maintained
With continued use
Comparison
Visceral Adipose Tissue Reduction Over Time
Week 26 - 15.4%
Week 52 - 17.5%
Placebo −5.0%
View the Trial Data
Extended Outcomes
Additional Metabolic and Systemic Effects